Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
206 participants
INTERVENTIONAL
2014-07-31
2020-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Control Group of Usual Physical Activity
2. Intervention Group of Increased Physical Activity
No specific intervention will be performed In the patients randomized in the control group.
Patients randomized in the Intervention group will receive a program of increased physical activity starting from 5000 steps/day up to 12000 steps/day after 8 weeks. At the same time patients of this group will receive an 8-week recreational program of brisk walking/running (3 times a week).
All the patients enrolled in this trial will receive a pedometer device (Garmin Vìvofit) able to count the number of steps, determine a daily goal of steps, determine the covered distance (in Km), determine daily caloric consumption, and determine the movements during sleep.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors
NCT03523195
Physical Activity Promotion in Breast Cancer Survivors
NCT00221221
Attitudes Toward Physical Activity and Nutrition Intervention During Cancer Treatment
NCT02887196
Physical Activity Promotion in Cancer Follow-Up Care
NCT00230711
Behavioural Changes in Breast Cancer Patients
NCT01990430
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Control Group of Usual Physical Activity
2. Intervention Group of Increased Physical Activity
No specific intervention will be performed In the patients randomized in the control group.
Patients randomized in the Intervention Group will receive a program of increased physical activity starting from 5000 steps/day up to 12000 steps/day after 8 weeks. At the same time patients of this group will receive an 8-week recreational program of brisk walking/running (3 times a week).
All the patients enrolled in this trial will receive a pedometer device (Garmin Vìvofit) able to count the number of steps, determine a daily goal of steps, determine the covered distance (in Km), determine daily caloric consumption, and determine the movements during sleep.
Data will be downloaded in a specific application available online (Garmin Connect).
All the patients will receive written information on the potential benefits of physical exercise and better lifestyle.
At baseline, at the end of the study period (8 weeks) and after 1 year patients will be asked to fill out the following questionnaires:
* Funcional Assessment of Cancer Therapy- Breast (FACT-B, 37 items)
* Patient reported symptoms (PRS like International Breast Cancer Study Group form, 19 items)
* Funcional Assessment of Cancer Therapy- Fatigue (FACT-Fatigue, 13 items)
* Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog; 37 items)
* Impact of Event Scale (IES; 22 items)
At baseline, at the end of the study period (8 weeks) patients will be asked to undergo blood draw for serum analysis of insulin, IGF-1, leptin, PCR, cholesterol, triglycerides leucocyte count, T lymphocyte subpopulations (T regulatory and TH17).
The hypothesis of the study is that even a short course of increased physical activity may improve quality of life of non-regular exercisers women with a personal history of breast cancer who completed treatment (endocrine treatment excluded).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
Usual Physical Activity
No interventions assigned to this group
Intervention Group
8-week increased physical activity program
Increased Physical Activity
Patients will receive a program of increased physical activity starting from 5000 steps/day up to 12000 steps/day after 8 weeks and an 8-week recreational program of brisk walking/running (3 times a week).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Increased Physical Activity
Patients will receive a program of increased physical activity starting from 5000 steps/day up to 12000 steps/day after 8 weeks and an 8-week recreational program of brisk walking/running (3 times a week).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent AND
* Willing to be randomized to either group AND
* Age 18-70 years
* Treatment (surgery, chemotherapy, radiotherapy, trastuzumab) completed since at least 6 months and up to 3 years (endocrine therapy allowed)
* Non regular exercisers (≤150 minutes per week of moderate-intense exercise).
Exclusion Criteria
* General contraindications to regular physical activity participation
* Inability to ambulate
* Plan to relocate far from the study site
* Presence of any severe medical condition such that the patient is not expected to adhere at the planned study protocol
18 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Institute of Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Oreste D Gentilini, MD
Role: PRINCIPAL_INVESTIGATOR
European Institute of Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
European Institute of Oncology
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IEO 121
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.